Microbiome MDx specialist Genetic Analysis and Bio-Rad Sign Agreement
November 28 2016 - 4:05PM
Business Wire
Bio-Rad to Commercialize Genetic Analysis’s GA-map Technology
for the Detection of Gut Dysbiosis
Genetic Analysis (GA) and Bio-Rad Laboratories, Inc., a
global provider of life science research and clinical diagnostic
products, today announced that they have signed an agreement in
which Genetic Analysis will receive an equity investment from
Bio-Rad in exchange for commercialization rights, in certain
territories, for Genetic Analysis’s GA-map™ technology to detect
gut dysbiosis. Terms of the agreement were not disclosed.
The patented GA-map™ technology is used as an aide in the
diagnosis and management of irritable bowel syndrome and
inflammatory bowel disease.
Dysbiosis is a microbial imbalance or maladaptation on or inside
the body and is most commonly reported as a condition in the
digestive tract. It has been associated with illnesses, such as
inflammatory bowel disease and other chronic
diseases.
“We are delighted to be linking up with Bio-Rad, a major force
for innovation in in vitro diagnostic testing,” said Ronny
Hermansen, CEO of Genetic Analysis. “We believe that this
collaboration will accelerate the penetration of the GA tests into
routine healthcare as the importance of the microbiome in major
diseases becomes increasingly recognised.”
“We welcome the opportunity to partner with Genetic Analysis,”
said Norman Schwartz, Bio-Rad President and CEO. “With the GA-map
technology, we can offer products to analyze the microbiome
associated with gut dysbiosis, which affects the quality of life of
many patients around the world and can result in serious health
problems.”
About Genetic Analysis
Genetic Analysis has developed and launched the first gene-based
routine test for the mapping and aide in diagnosis of diseases
related to dysbiosis and imbalances in the bacteria in the
digestive system. The company markets the GA-map™ technology to
three market segments: commercial routine testing, pharma companies
and the research market. Genetic Analysis was established in 2008
and is based on research done by Professor Knut Rudi at Norwegian
University of Life Sciences, NMBU and Nofima Mat in Ås.
www.genetic-analysis.com
About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) develops,
manufactures, and markets a broad range of innovative products and
solutions for the life science research and clinical diagnostic
markets. The company is renowned for its commitment to quality and
customer service among university and research institutions,
hospitals, public health and commercial laboratories, as well as
the biotechnology, pharmaceutical, and food safety industries.
Founded in 1952, Bio-Rad is based in Hercules, California, and
serves more than 100,000 research and health care industry
customers through its global network of operations. The company
employs more than 8,000 people worldwide and had revenues exceeding
$2 billion in 2015. For more information, please
visit http://bio-rad.com.
This release may be deemed to contain certain forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. These forward-looking statements include,
without limitation, statements we make regarding plans to
commercialize the GA-map™ technology and our development and launch
of new products. Forward-looking statements generally can be
identified by the use of forward-looking terminology such as
“plan”, “believe,” “expect,” “anticipate,” “may,” “will,” “intend,”
“estimate,” “continue,” or similar expressions or the negative of
those terms or expressions, although not all forward-looking
statements contain these words. Such statements involve risks and
uncertainties, which could cause actual results to vary materially
from those expressed in or indicated by the forward-looking
statements. These risks and uncertainties include our ability to
develop and market new or improved products, our ability to compete
effectively, international legal and regulatory risks, and product
quality and liability issues. For further information regarding our
risks and uncertainties, please refer to the “Risk Factors” and
“Management’s Discussion and Analysis of Financial Condition and
Results of Operation” in Bio-Rad’s public reports filed with the
Securities and Exchange Commission, including our Annual Report on
Form 10-K for the fiscal year ended December 31, 2015 and our
Quarterly Report on Form 10-Q for the fiscal quarter ended
September 30, 2016. Bio-Rad cautions you not to place undue
reliance on forward-looking statements, which reflect an analysis
only and speak only as of the date hereof. We disclaim any
obligation to update these forward-looking statements.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161128006022/en/
Genetic AnalysisRonny Hermansen, +47 924 56
704rh@genet-analysis.comorBio-Rad Laboratories, Inc.Tina Cuccia,
510-724-7000Corporate Communicationstina_cuccia@bio-rad.com
Bio Rad Laboratories (NYSE:BIO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bio Rad Laboratories (NYSE:BIO)
Historical Stock Chart
From Apr 2023 to Apr 2024